2268 (2268) Fair Value & Analysis
Healthcare · Market cap HK$74.1B
Fair value as of: Jul 2, 2026
From 26 valuation models · updated today
Share price +7.4% over the past month.
Price vs Fair Value (12 months)
12‑month range HK$39.90 – HK$85.10 · fair‑value band HK$12.87 – HK$39.12 · the HK$58.80 price screens above the HK$21.28 fair value. As of Jul 2, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
2268 (2268) currently trades at HK$58.80, while our model-based Fair Value estimate is HK$21.28 — implying the stock looks roughly 63.8% overvalued today. We read business quality at 53/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, 2268 generated revenue of HK$5.9B at a net margin of 24.9%. Revenue grew 35.9% year over year. It earns a return on equity of 17.1%. The balance sheet holds a net cash position of HK$632M. Fundamentals as of Jul 2, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
2268 reported revenue of HK$5.9B in FY2025 versus HK$311M in FY2021, a compound +109.1%/yr. Reported net income was HK$1.5B in FY2025, compounding +127.9%/yr from FY2021.
Is 2268 fairly valued? → Check now
Recent news
- WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility
- Stronger Together, Shaping the Future | WuXi XDC and BioDlink Successfully Concluded 2026 Open Day
- Global In Focus With 3 Stocks Considered By Analysts As Undervalued
- April 2026's Global Stocks Estimated Below Intrinsic Value
External third-party headlines (Yahoo Finance, Reuters and others) — not an editorial selection, not financial advice.
Similar stocks
6 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $472.80 | $190.31 | -60% |
| Danaher Corporation DHR | $178.19 | $112.34 | -37% |
| 2359 2359 | HK$152.80 | HK$120.99 | -21% |
| WuXi AppTec Co WUXAY | $18.59 | $25.09 | +35% |
| IDEXX Laboratories, Inc IDXX | $556.94 | $255.77 | -54% |
| Lonza Group LZAGY | $63.74 | $25.98 | -59% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is 2268 (2268) undervalued?
What is the fair value of 2268?
What is the quality score of 2268?
What is the revenue of 2268 (2268)?
What is the net profit margin of 2268?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.